New developments for antibody-drug conjugate-based therapeutic approaches

Curr Opin Immunol. 2016 Jun;40:14-23. doi: 10.1016/j.coi.2016.02.008. Epub 2016 Mar 7.

Abstract

The clinical success of Adcetris(®) (brentuximab vedotin) and Kadcyla(®) (ado-trastuzumab emtansine) has sparked clinical development of novel ADCs. These powerful anti-cancer agents are designed to allow specific targeting of highly potent cytotoxic agents to tumor cells while sparing healthy tissues. Despite the use of tumor-specific antibodies, the emerging clinical data with ADCs indicates that adverse effects frequently occur before ADCs have reached their optimal therapeutic dose, resulting in a relatively narrow therapeutic window. This review summarizes the therapeutic window of ADCs currently in clinical development, along with some strategies that may help to widen the window.

Publication types

  • Review

MeSH terms

  • Ado-Trastuzumab Emtansine
  • Animals
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Brentuximab Vedotin
  • Clinical Protocols
  • Drug-Related Side Effects and Adverse Reactions
  • Humans
  • Immunoconjugates / therapeutic use*
  • Immunotherapy / methods*
  • Immunotherapy / trends
  • Immunotoxins / therapeutic use*
  • Maytansine / analogs & derivatives*
  • Maytansine / therapeutic use
  • Neoplasms / immunology
  • Neoplasms / therapy*
  • Risk Assessment
  • Trastuzumab

Substances

  • Antibodies, Monoclonal, Humanized
  • Immunoconjugates
  • Immunotoxins
  • Maytansine
  • Brentuximab Vedotin
  • Trastuzumab
  • Ado-Trastuzumab Emtansine